13 completed. 13 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 13 | Completed 13 |
Follow Deep Vein Thrombosis: new trials by email Literature Review of Deep Vein Thrombosis trials Research Report on Deep Vein Thrombosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism Apixaban 2.5 MG, Placebo oral tablet - Deep Vein Thrombosis, Pulmonary Embolism | Phase 4 | Completed | Brigham and Women's Hospital | 600 | 2021-03-01 | 2025-11-14 |
| Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19 Enoxaparin - COVID, Thrombosis | Phase 4 | Completed | Central Hospital, Nancy, France | 1000 | 2020-05-13 | 2023-08-07 |
| Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis Rivaroxaban, Diosmin, compression stockings - Deep Vein Thrombosis, Postthrombotic Syndrome | Phase 4 | Completed | Pirogov Russian National Research Medical University | 90 | 2017-12-20 | 2021-02-04 |
| Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular System EkoSonic® Endovascular System, Alteplase - Deep Vein Thrombosis, Post-thrombotic Syndrome | Phase 4 | Completed | Boston Scientific Corporation | 81 | 2014-07-10 | 2021-07-19 |
| Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin 5000 Units unfractionated Heparin Q 8 hr, 30mg enoxaparin Q12 hr - Venous Thromboembolic Disease, Deep Vein Thrombosis | Phase 4 | Completed | Scripps Health | 495 | 2012-11-01 | 2016-07-18 |
| Echo-Doppler Assessment of the Occurrence of Asymptomatic DVT in Orthopedic Replacement Surgery Under Enoxaparin Enoxaparin - Deep Vein Thrombosis, Venous Thrombosis | Phase 4 | Completed | Les Laboratoires des Médicaments Stériles | 153 | 2011-03-01 | 2015-11-03 |
| Comparison of Warfarin Dosing Using Decision Model Versus Pharmacogenetic Algorithm Warfarin Dose based on pharmacogenetics - Atrial Fibrillation, Pulmonary Embolism | Phase 4 | Completed | Creighton University | 102 | 2006-08-01 | 2012-12-11 |
| Innohep® in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis innohep®, Heparin - Deep Vein Thrombosis | Phase 4 | Completed | LEO Pharma | 541 | 2005-12-01 | 2025-03-06 |
| Residual Vein Thrombosis Establishes the Optimal Duration of Oral Anticoagulants Warfarin - Deep Vein Thrombosis | Phase 4 | Completed | Azienda Ospedaliera Universitaria Policlinico | 250 | 2003-11-01 | 2007-02-22 |
| D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism Vitamin K antagonist (Coumarin anticoagulants) - Deep Vein Thrombosis, Pulmonary Embolism | Phase 4 | Completed | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 600 | 2002-09-01 | 2021-03-19 |
| The D-KAF (Dalteparin in Knee-to-Ankle Fracture) Trial Low Molecular Weight Heparin (dalteparin) - Deep Vein Thrombosis, Pulmonary Embolism | Phase 4 | Completed | Sunnybrook Health Sciences Centre | 700 | 2002-08-01 | 2007-02-27 |
| 3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE Duration of anticoagulation, Warfarin duration - Deep Vein Thrombosis, Pulmonary Embolism | Phase 4 | Completed | British Thoracic Society | 2400 | 1999-09-01 | 2006-08-18 |
| Absence of Residual Vein Thrombosis Permits to Withdrawn Oral Anticoagulants warfarin accordingly INR value - Deep Vein Thrombosis | Phase 4 | Completed | Azienda Ospedaliera Universitaria Policlinico | 500 | 1999-06-01 | 2008-03-25 |
Venous Thrombosis (13) · Pulmonary Embolism (7) · Venous Thromboembolism (3) · Postthrombotic Syndrome (2) · Thrombosis (2) · Atrial Fibrillation (1) · Recurrence (1) · Tibial Fractures (1) · Wounds and Injuries (1)
Cardiovascular Diseases (13) · Embolism and Thrombosis (13) · Vascular Diseases (13) · Thrombosis (11) · Embolism (7) · Lung Diseases (7) · Respiratory Tract Diseases (7) · Thromboembolism (3) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Venous Insufficiency (2) · Arrhythmias, Cardiac (1) · Disease Attributes (1) · Fractures, Bone (1) · Heart Diseases (1)
Enoxaparin (3) · Dalteparin (2) · Heparin, Low-Molecular-Weight (2) · Tinzaparin (2) · Warfarin (2) · Diosmin (1) · Heparin (1) · Nadroparin (1) · Rivaroxaban (1) · Stockings, Compression (1) · Tissue Plasminogen Activator (1) · apixaban (1)
Azienda Ospedaliera Universitaria Policlinico (2) · Boston Scientific Corporation (1) · Brigham and Women's Hospital (1) · British Thoracic Society (1) · Central Hospital, Nancy, France (1) · Creighton University (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · LEO Pharma (1) · Les Laboratoires des Médicaments Stériles (1) · Pirogov Russian National Research Medical University (1) · Scripps Health (1) · Sunnybrook Health Sciences Centre (1)
United States (3) · France (2) · Italy (2) · Bulgaria (1) · Canada (1) · Croatia (1) · Czechia (1) · Germany (1) · Poland (1) · Romania (1) · Russia (1) · Serbia (1) · Spain (1) · Tunisia (1) · United Kingdom (1)
Sergio Siragusa, MD (2) · Abdelaziz Zarrouk, MD (1) · Alain Leizorovicz, MD (1) · Aziz Sheikh, MD,FRCGP (1) · Christopher J. Destache, Pharm. D. (1) · El Mehdi Siaghy (1) · Ilya Schastlivtsev, PhD (1) · Mark Garcia, MD (1) · Mustapha Azaiz, MD (1) · Ramzi Bouzidi, MD (1) · Rita Selby, MBBS, FRCPC (1) · Steven R Shackford, MD (1) · William Geerts, MD, FRCPC (1)
PMID 17065639, PMID 17289685, PMID 18497320, PMID 20352167, PMID 20553388, PMID 21477846, PMID 21953853, PMID 23306310, PMID 25900749, PMID 31983322, PMID 33201130, PMID 33502773, PMID 35244208, PMID 37350990, PMID 40888734